Pharmaceuticals company Hester Biosciences announced Q2FY25 results Revenue from operations: Rs 836.92, compared to Q2FY24 Rs 704.55 change 19%. Consolidated EBITDA: Rs 219.55 million change 15% Q2FY25 Consolidated Divisional Product sales up by 21% & Profit up by 108%. Hester Nepal achieved net profit of Rs 0.29 million in Q2FY25, reversing from a loss of Rs 7.05 million in Q2FY24. The subsidiary fulfilled export orders from government tenders and met domestic vaccine demand, showcasing its growth potential. Hester Nepal remains debt-free with strong cash flows from the quarter. Hester Africa reduced its net loss to Rs 23.67 million in Q2FY25, down from net loss of Rs 49.17 million in Q2FY24. Hester Africa is actively participating in international tenders and meeting trade demands across various African countries, with increasing awareness and demand for vaccines. Result PDF